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Abstract
Background/Aims: Systemic hyperlipidemia and intracellular lipid accumulation induced by 
chronic high fat diet (HFD) leads to enhanced fatty acid oxidation (FAO) and ketogenesis. 
The present study was aimed to determine whether activation of peroxisome proliferator-
activated receptor-γ (PPAR-γ) by surplus free fatty acids (FA) in hyperlipidemic condition, 
has a positive feedback regulation over FAO and ketogenic enzymes controlling lipotoxicity 
and cardiac apoptosis. Methods: 8 weeks old C57BL/6 wild type (WT) or PPAR-γ-/- mice were 
challenged with 16 weeks 60% HFD to induce obesity mediated type 2 diabetes mellitus 
(T2DM) and diabetic cardiomyopathy. Treatment course was followed by echocardiographic 
measurements, glycemic and lipid profiling, immunoblot, qPCR and immunohistochemistry 
(IHC) analysis of PPAR-γ and following mitochondrial metabolic enzymes 3-hydroxy-3-
methylglutaryl-CoA synthase (HMGCS2), mitochondrial β- hydroxy butyrate dehydrogenase 
(BDH1) and pyruvate dehydrogenase kinase isoform 4 (PDK4). In vivo model was translated 
in vitro, with neonatal rat cardiomyocytes (NRCM) treated with PPAR-γ agonist/antagonist 
and PPAR-γ overexpression adenovirus in presence of palmitic acid (PA). Apoptosis was 
determined in vivo from left ventricular heart by TUNEL assay and immunoblot analysis. 
Results: We found exaggerated circulating ketone bodies production and expressions of the 
related mitochondrial enzymes HMGCS2, BDH1 and PDK4 in HFD-induced diabetic hearts 
and in PA-treated NRCM. As a mechanistic approach we found HFD mediated activation of 
PPAR-γ is associated with the above-mentioned mitochondrial enzymes. HFD-fed PPAR-γ-/- 
mice display decreased hyperglycemia, hyperlipidemia associated with increased insulin 
responsiveness as compared to HFD-fed WT mice PPAR-γ-/--HFD mice demonstrated a 
more robust functional recovery after diabetes induction, as well as significantly reduced 
myocyte apoptosis and improved cardiac function. Conclusions: PPAR-γ has been described 
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previously to regulate lipid metabolism and adipogenesis. The present study suggests for the 
first time that increased PPAR-γ expression by HFD is responsible for cardiac dysfunction via 
upregulation of mitochondrial enzymes HMGCS2, BDH1 and PDK4. Targeting PPAR-γ and its 
downstream mitochondrial enzymes will provide novel strategies in preventing metabolic and 
myocardial dysfunction in diabetes mellitus.
IntroductionChronic HFD induction is associated with dysregulated glucose and lipid metabolism and thus, overall dysregulated energy homeostasis [1-3]. Shifting in the energy balance is the major cause for insulin resistance, obesity and T2DM. The overall prevalence of insulin 
resistance and T2DM in developed societies is alarmingly high, afflicting 30% of American 
adults and about 14% of the European adults [4-6]. The combination of obesity and T2DM 
contributes significantly to the rise in cardiovascular diseases.
During HFD-mediated T2DM, lipids accumulate, FAO is enhanced, and cardiomyocyte apoptosis subsequently occurs in a process collectively known as lipoapoptosis. This has 
been proposed to play a significant role in the development of cardiovascular diseases [7-
10]. However, the mechanisms that lead to diabetes-induced heart disease are complicated 
and remain largely unknown [9]. Evidence supports an association between chronic hyperlipidemia and morphological and functional changes in hearts. Many of these changes, including cardiac hypertrophy and compromised left ventricular (LV) function, are believed 
to be precursors of more exaggerated forms of cardiac dysfunction and heart failure [11-16].The cardiac structural and functional changes result from a dramatic metabolic shift that takes place in diabetic hearts: the hyperlipidemic environment impairs glucose uptake by decreased expression and translocation of Glut4/Glut1 receptors. To compensate 
for the decrease in glucose, FA metabolism becomes the major conduit of energy supply 
to support cardiac functions. As a vicious cycle, increased myocardial FA intake makes the 
cardiomyocytes to lose the ability to use glucose more, leading to cardiac metabolic inflexibility. 
Dependence of heart muscle on FAO over glucose oxidation leads to hyperglycemia and 
insulin resistance [17-19]. Studies have shown that during the development of T2DM and in diabetic db/db mice, there is a decrease in glucose oxidation and an increase in reliance on 
FAs [17, 20-22].
In diabetic heart, the characteristic disturbances in myocardial energy and FA 
homeostasis are regulated by PPAR transcription factors by governing the expressions of key 
proteins in FA metabolic pathways [23-27]. Activation of PPARs leads to an increase in free 
FA uptake and oxidation, corresponding to the level of insulin resistance in cardiomyocytes 
[20]. This exaggerated reliance on FA metabolism decreases the overall efficacy of the heart by increasing the oxygen consumption to create the needed energy, resulting in lipotoxicity. The 
FA-driven activation of PPAR transcription factors regulates the expression of target genes, 
affecting uptake, oxidation, and storage of FAs [28]. Among the three isoforms exist, α, β/δ, 
and γ, PPAR-γ is mostly activated by free FA and eicosanoids and predominantly expressed in adipose tissues and, to a lesser extent, in other tissues including heart, regulating lipid 
metabolism [29, 30].
For ATP production, the mitochondrial enzyme complex pyruvate dehydrogenase (PDH) 
utilizes glycolytically-derived pyruvate, and cardiac PDH activity is mostly regulated by PDK4 
(EC 2.7.11.2). The expression of PDK4 rapidly increases along with the increased availability 
of FAs over glucose during the generation of HFD-mediated T2DM. This metabolic shift 
causes diet-induced loss of mitochondrial pyruvate utilization and the ensuing development 
of insulin resistance in the heart [31-40].
The high rate of FAO in T2DM patients increases production of high-energy phosphates, 
acetyl CoA and NADH, which are converted to ketone bodies through ketogenesis. In diabetic condition the ketone bodies serve as an important glucose- sparing fuel source [41, 42]. In 
mitochondria, a series of ketogenic reactions are catalyzed by mitochondrial thiolases, among 
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which mitochondrial HMGCS2 (EC 2.3.3.10) is the rate-limiting enzyme for ketogenesis that 
converts acetyl CoA derived from β-oxidation of FAs to acetoacetate (AcAc) [43, 44]. The 
AcAc in turn is reduced by BDH1 (EC 1.1.1.30) to β-hydroxy butyrate (βOHB) [42, 43]. We recently showed that HMGCS2 was most upregulated gene in type I diabetic heart of mice 
model which is also an indirect reflection of exaggerated HMGCS2 activity as the rate limiting 
enzyme of this pathway [44]. Interestingly other previous findings showed HMGCS2 and 
PDK4 genes are transcriptionally regulated by PPAR-γ via PPAR responsive element (PPRE) 
and PPAR-γ coactivator 1 (PGC-1) [45, 46]. But there is no study found till date that provide 
insight if PPAR-γ can regulate the activities of HMGCS2, BDH1 and PDK4 at protein levels and if that differential regulation may have a potential effect on cardiac structure and function in hyperlipidemic environment at long run.
Relying on these background evidences supported by our data, we demonstrate for the 
first time that PPAR-γ being activated by high intracellular contents of free fatty acids in a 
lipid rich environment induces the expressions of ketogenic enzymes HMGCS2, BDH1 and 
PDK4, the regulatory enzyme for PDH complex. Also our data showed how upregulation 
of the above mentioned enzymes are correlated with lipotoxicity and cardiac dysfunction. 
Hence, we postulate that PPAR-γ antagonism may provide a novel therapeutic strategy for preventing adverse effects from HFD mediated T2DM and cardiac abnormalities.
Materials and Methods
Animals and diet
C57BL/6 male mice, 8 weeks of age, were purchased from the Jackson Laboratory (Bar Harbor, Maine). 
Mice were housed at Thomas Jefferson University animal facility under standard conditions (12/12 light-
dark cycle, humidity at 50 ± 15%, temperature 22 ± 2°C). They were either fed with standard diet (13% kcal 
from fat) or high fat diet (60% kcal from fat, Research diets, New Brunswick, NJ, cat. no. D12492) for 16 
weeks [47]. Body weight, food intake, and blood glucose were recorded weekly. All animal protocols have 
been approved by the Institutional Animal Care Committee of Thomas Jefferson University, and experiments conformed to the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes 
of Health and approved by the American Physiological Society.
Rosa26-CreERT2-PPAR-γflox/flox mice were a generous gift from Dr. Richard Pestell, Blumberg Institute. 
These mice were generated according to previous publication [48]. To induce Cre-dependent recombination, 
tamoxifen (20 mg/kg body weight, Sigma- Aldrich) was injected into 6-weeks-old animals intraperitoneally 
for 5 days [49]. Ubiquitous PPAR-γ deficiency was achieved 1 week after injection as verified by western 
blot analysis. For easier reading, we refer to these mice as PPAR-γ-/- mice. They were paired with age- and 
sex-matched PPAR-γWT/WT littermates for all experiments.
Genotyping of mice
The PPAR-γflox/flox and PPAR-γwt/wt alleles and the Cre transgene were detected in mouse tail DNA 
by PCR. Primers for PPAR-γflox/flox and PPAR-γwt/wt result in a 285 bp and a 233 bp product, respectively. 
The primer sets used are: Flox-PPAR-γ (Forward 5’- CTCCAATGTTCTCAAACTTAC -3’; Reverse, 5’- 
GATGAGTCATGTAAGTTGACC -3’); Rosa26(Forward 5’- AAAGTCGCTCTGAGTTGTTAT -3’; Reverse 5’- 
GGAGCGGGAGAAATGGATATG -3’), CRE-ER (5’- CCTGATCCTGGCAATTTCG-3’).
We labeled four groups of mice: WT-chow, WT-HFD, PPAR-γ-/--chow and PPAR-γ-/-- HFD. After 16 weeks 
of treatment, mice were sacrificed for experimental measurements.
Hemodynamic and Echocardiographic measurement
Echocardiographic measurements were taken before and after 16 weeks of HFD treatment to determine the baseline heart function and ventricular dimensions in the experimental groups. Cardiac 
function and ventricular dimensions were calculated as described previously [49]. Briefly, following light 
sedation with 1% Isoflurane, mice were placed on a platform in left lateral decubitus position for imaging. 
All hairs were removed from chest area using chemical hair remover and aquasonic clear ultrasound gel 
(Parker Laboratories, Fairfield, NJ) without bubbles was applied to the thorax surface to optimize the 
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visibility of the cardiac chambers. Echocardiography was done using Visualsonic Ultrasound System (Vevo 
2100, Toronto, Canada) as described earlier [50]. Standard long axis M-Mode and PW droppler mode views 
were recorded when the mouse possessed a target heart rate between 450 and 550 beats per minute. 
Left ventricular (LV) mass, E/A ratio, and percent ejection fraction (%EF) and fractional shortening (% FS) were calculated.
NRCM isolation and treatment
Cardiomyocytes were isolated from the ventricles of Sprague-Dawley rat pups using enzymatic 
digestion [51]. Briefly, hearts were removed from 1-2 days old pups, digested in perfusion buffer containing 
type II collagenase (Worthington Biochemical Corp., Lakewood, NJ) to dissociate ventricular myocytes. After 
isolation, cells were pre-plated for 30 minutes to avoid non-myocyte populations. Then myocytes were 
recollected and plated in collagen coated dishes (Sigma-Aldrich) at a density of 160, 000/cm2 in 10% calf 
bovine serum (CBS) DMEM supplemented with 1 mmol/liter L-glutamine, antibiotic/antimycotic solution, 
and 100 µmol/L 5-bromo-2-deoxyuridine (BrdU). The cells were maintained at 37 °C in 95% humidified 
atmosphere, containing 5% CO2 concentration. Under these high density conditions, the myocytes form cell-cell contacts and display spontaneous contractile activity within 24 hours of plating.
Caspase 3/7 apoptotic staining
Cells were kept in DMEM media supplemented with 10% calf bovine serum (CBS), 1 mmol/liter 
L-glutamine, antibiotic/antimycotic solution and treated with different concentrations of D,L sodium-βHB 
(Sigma-54965)  (0.1-100 mM) for 12 hours, fixed  with PFA and stained with caspase 3/7 kit (Thermo fisher, 
PA, USA) and counterstained with DAPI.
Serum lipid profile
Total cholesterol (TC), free FAs and triglycerides (TG) were measured from serum using colorimetric 
kits from Biovision (Milpitas, CA) according to the manufacturers’ protocol. Briefly, serum sample was 
mixed with assay buffer and enzyme mix, incubated in dark and measured at 570 nm using a plate reader. 
Quantification was done from standard curve using the corresponding standards for cholesterol, TG, or FA.
Serum Insulin
Serum insulin was measured using ELISA kit from Millipore (Billerica, MA, EZRMI-13K) according to 
the manufacturers’ protocol.
Serum ketone body measurement:
Serum βOHB was measured using a colorimetric kit from Biovision (K632) according to the 
manufacturer’s protocol. Briefly, serum sample was mixed with assay buffer and enzyme mix and substrate 
mix, incubated and measured at 450 nm using a plate reader. Quantification was done from standard curve using the corresponding standards.
Immunohistochemistry (IHC)
Tissues were fixed in 10% formalin, embedded in paraffin, and sectioned at 5 µm thickness. Paraffin 
heart sections were deparaffinized in xylene and rehydrated. Antigen retrieval was achieved by boiling 
the slides in citrate solution for 20 minutes and slides were then washed with phosphate-buffered Saline 
(PBS). After quenching endogenous tissue peroxidase activity with 3% H2O2 for 15 minutes, slides were then 
washed in PBS and blocked in PBS containing 2.5% serum at room temperature for 30 minutes. Primary 
antibodies to detect PPAR-γ and HMGCS2 (Abcam, Cambridge, MA), or PDK4 (Thermo Fisher, Rockford, 
IL) were applied overnight at 4°C in PBS containing 2.5% serum. The next day, samples were washed in 
PBS and then sequentially incubated with Vectastain Elite ABC Kit (Avidin/Biotin/Horseradish Peroxidase-
System (Vector Laboratories)). The peroxidase reaction was visualized using 3, 3’-diaminobenzidine 
tetrahydrochloride (DAB) and slides were counterstained with hematoxylin.
Histopathology of the heartTransverse section of heart containing both ventricles together from each mouse was cleaned, 
processed and embedded in paraffin wax. Paraffin blocks were cut by rotary microtome at 5 µm thickness. The sections processed and stained with hematoxylin and eosin for morphological evaluation of the heart and with picrosirius red for collagen deposition. The stained slides were observed using a compound 
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microscope (Nikon, USA) at 200x magnification. The photographs were analysed and quantified with ImageJ software.
Oil-red-o staining
Fresh frozen heart sections (6 µm) were fixed on ice cold 10% formalin for 5-10 minutes, air dried 
and treated with propylene glycol for few minutes. Stained in pre- warmed Oil Red O solution in 60 ºC oven 
and differentiate in 85% propylene glycol for 2-5 mins. Rinse with distilled water and counter stained in haematoxylin.
Immunoblot analysis
Extraction of proteins from heart tissue samples and NRCM was performed as described previously [49]. 
in brief, heart tissue was homogenised and cell lysates were obtained in FAK lysis buffer (50 mM Tris-HCl, 
pH 7.5, 100 uM sodium pyrophosphate, 1 mM sodium fluoride, 150 mM NaCl, 0.1% SDS, 1% triton X-100, 0.5 
mM EDTA) containing protease and phosphatase inhibitors. The lysates were obtained by centrifugation and 
the supernatants were subjected to immunoblotting analysis according to the manufacturers’ instructions. 
Each panel in each figure represents results from a single gel exposed for a uniform duration, with bands 
detected by LI-COR Odyssey imaging system (LI-COR, Inc., Nebraska USA). PPAR-γ and HMGCS2 (Abcam, 
Cambridge, MA). BDH1 and PDK4 (Thermofisher, Rockford, IL). Glut4 (Bioss, Woburn, MA), Bax, Histone 3, 
Cytochrome c, and Bad (Cell Signaling Technology, Danvers, MA). GAPDH (Millipore, Billerica, MA).
Assessment of apoptosis by TUNEL assay
Determination of apoptosis was done from paraffin embedded LV section by DeadEnd™ Fluorometric 
TUNEL assay kit (Promega, Madison, WI) according to the manufacturers’ protocol.
Quantitative real-time (qRT) PCR
Total RNA were extracted from LV tissue with TRIZOL. cDNA was generated from 2µg of total RNA 
using High Capacity RNA-to-cDNA kit (Life Technology Grand Island, NY) according to the manufacturer’s 
instruction. qRT-PCR assays were performed using PerfeCT Super Green Super Mix (Quanta Biosciences, 
Beverly, MA) by using specific primers PPAR-γ, HMGCS2, BDH1 and PDK4 (Invitrogen, Carlsbad, CA) 
Differences in expression were determined by the relative quantification method; the cycle threshold (CT) 
values of the target genes were first normalized to the CT values of endogenous control GAPDH. All primer sequences are given in Table 1.
PPAR-γ retrovirus preparation and infection
The MSCV-IRES-GFP retrovirus vector and the vector pSV-ψ-E-MLV that provides ecotropic packaging 
helper function and infection methods were described previously [52, 53]. Retroviruses were prepared by 
transient co-transfection of vector expressing PPAR-γ, PγCA and empty vector together with the helper viral vector into 293T cells, using calcium phosphate precipitation. The retroviral supernatants were harvested 
48 h after transfection and filtered through a 0.45 µm filter. NRCMs were incubated with fresh retroviral 
supernatants in the presence of 5 µg/ml polybrene for 24 h, cultured for a further 48 hrs, and subjected to western blot analysis.
Data analysis
All values recorded are expressed as the mean ± standard error of the mean. Statistical analysis, such 
as one-way ANOVA followed by post hoc analysis, was done using Graph pad version 4.0 software (San 
Diego, CA, USA). A value of *p < 0.05 (denoted as *chow vs HFD, # WT-HFD vs PPAR-/--HFD) was considered 
significant.
Results
Chronic HFD consumption causes systemic 
hyperglycemia and hyperlipidemiaTo examine the contribution of HFD on body 
weight, blood glucose and blood lipid levels, WT 
mice were fed with 60% HFD for 16 weeks. Body weight and blood glucose levels were progressively 
Table 1. List of Primer sequence used for 
qRT PCR
Gene Forward (5’-3’) Reverse (5-3’) HMGCS2 CCGTATGGGCTTCTGTTCAG AGCTTTGTGGGTTCCATCA PDK4 CAAAGACGGGAAACCCAAGCC CGCAGAGCATCTTTGCACAC BDH1 GAATTCAGCCTGCCGGTTTG TGCATCCCGCTGTCAGGTAA PPAR-y GCCCTTTGGTGACTTTATGGA GCAGCAAGGTTGTCTTGGATG GAPDH GGCAAATTCAACGGCACA GTTAGTGGGGTCTCGCTCTG 
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and significantly increased during the experimental period in HFD-WT mice compared to WT-
chow mice (Fig. 1A & 1B). Impaired glucose tolerance and diminished insulin responsiveness were evident in HFD-mice from their respective patterns of glucose and insulin tolerance 
curves (Fig. 1C & 1D). The insulin resistance was further confirmed by an 8.5 fold increase 
in serum insulin level in WT- HFD group over its counterpart (Fig. 1E). High body weight 
and hyperglycemia were correlated with high levels of blood cholesterol and free FAs in 
HFD-mice. Total Cholesterol (TC) and total free FAs were increased by 2.1 fold and 3.6 fold, 
respectively in WT-HFD compared to WT-chow group (Fig. 1F & 1G). Oil-red-O staining 
showed that lipid deposition in LV heart of WT-HFD group was more than 2 fold higher than 
in the LV heart WT-chow group (Fig. 1H & 1I).
HFD-mediated T2DM leads to ventricular hypertrophy and induced cardiac dysfunctionTo determine the effect of prolonged HFD treatment on cardiac physiology, heart weight 
and tibia length were measured during the sacrifice. Heart weight was increased by 35% and 
tibia length/heart weight ratio was increased by 20% in WT-HFD group compared to chow, 
indicating cardiac hypertrophy in WT-HFD group (Fig. 2A & 2B).To determine the impact of HFD-mediated T2DM on cardiac function, we performed 
echocardiography after 16 weeks of treatment (Fig. 2C-2H). Compared with WT-chow mice, 
the WT-HFD mice had significant reduction 
in LV ejection fraction (EF), LV fractional 
shortening (FS), and E/A ratio (Fig. 2C, 2D, 
2H). Additionally, the LV internal diameter 
diastole dimension (LVID;d), LV internal 
diameter systole (LVID;s), and LV posterior 
wall thickness (LVPW;d) were increased 
significantly in the WT-HFD group compared 
to the WT-chow group (Fig. 2E-2G).
Ketone bodies play a crucial role in HFD-
mediated cardiomyocyte lipotoxicity
In order to validate our findings from microarray data (data not shown), we 
performed qPCR and immunoblot to check 
the expression at the mRNA and protein levels of three mitochondrial metabolic 
enzymes: HMGCS2, BDH1 and PDK4 (Fig. 
3A-3C). Expression mRNA of HMGCS2, 
BDH1, and PDK4 was increased by 3.3 
fold, 1.7 fold and 2.3 fold, respectively 
in WT-HFD group compared to chow 
group (Fig. 3A). The protein expression 
of these enzymes was also significantly 
increased in WT-HFD group compared to 
WT-chow group (Fig. 3B & 3C). HFD mice also experienced a dramatic rise in serum 
βOHB concentrations (100% increase) over control (Fig. 3D). The overexpressed 
ketogenic enzymes were reflected in very high levels of ketone bodies in the blood due to chronic HFD induction.To determine whether ketone bodies 
are sufficiently toxic to induce apoptosis, 
we treated NRCMs with βOHB at different 
concentrations. We found that apoptosis started from as low as 1mM concentration 
Fig. 1. Chronic HFD consumption causes systemic 
hyperglycemia and hyperlipidemia. (A) Body weight 
(BW); (B) Blood glucose (BG); (C) Glucose tolerance 
test (GTT); (D) Insulin tolerance test (ITT), (E) Serum insulin, (F) Serum total cholesterol (TC), (G) Serum 
free fatty acids (FFA) in chow and HFD C57BL/6 
treated mice. Oil-red- O staining of LV heart (H) and 
its quantification (I) in chow and HFD mice (*p<0.05 vs chow).
Figure 1 
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and by 100 mM concentration most of the myocyte populations were apoptotic. 10 mM concentration was found to be the LD
50
 for βOHB treatment to the myocytes (Fig. 3E & 3F).
HFD-mediated T2DM leads to activation and nuclear translocation of PPAR-γ
As a regulatory factor for lipid metabolism and adipogenesis [39], next we determined 
the expression of PPAR-γ in LV heart by qPCR and IHC. We found almost 2 fold increase in 
mRNA expression of PPAR-γ in the HFD-WT LV heart compared to the chow-WT LV heart 
(Fig. 4A). Quantification of IHC data revealed over 5 fold increase in PPAR-γ positive cells in 
HFD-LV heart compared to its control (Fig. 4B & 4C).In order to check the nuclear translocation upon activation, next we checked the 
expression of PPAR-γ both from nuclear and cytosolic extracts. We found a significant 
increase in nuclear expression of PPAR-γ in WT-HFD group compared to control but no 
difference was observed in its cytosolic expression (Fig. 4D & 4E). This data confirms the 
nuclear translocation of PPAR-γ after T2DM induction by HFD.
PPAR-γ activation by HFD upregulates the expression of HMGCS2, BDH1 and PDK4
Immunoprecipitation (IP) from LV heart tissues lysates of HFD animals with specific 
PPAR-γ antibody followed by an immunoblot with specific antibodies to HMGCS2, BDH1, and 
PDK4 individually showed positive correlation between PPAR-γ HMGCS2, BDH1 and PDK4 
as compared to control hearts (Fig. 5A & 5B).
Fig. 2. HFD-mediated T2D leads ventricular hypertrophy and induced cardiac dysfunction. 
(A) Heart weight (HW), (B) Heart weight/Tibia 
length (HW/TL) ratio in chow and HFD mice. 
Echocardiographic analysis of (C) left ventricular 
(LV) fractional shortening (FS), (D) LV Ejection 
Fraction (EF), (E) Left ventricular posterior wall end 
diastole (LVPW;d), (F) left ventricle internal diameter, 
diastole (LVID;d), (G) left ventricle internal diameter, 
systole (LVID;s) and (H) E/A ratio in control and HFD 









Fig. 3. HFD-mediated T2D leads to cardiomyocyte 
lipotoxicity via ketone body synthesis. (A) qRT-PCR 
expressions of HMGCS2, BDH1, and PDK4 mRNAs 
from LV heart in bar diagram normalized with 
GAPDH internal control in chow and HFD group. (B-
C) Immunoblot expression of HMGCS2, BDH1, and 
PDK4 proteins from LV heart and their quantification 
normalized with GAPDH control in chow and HFD 
group. (D) Serum levels of β-hydroxy butyrate (β-HB) 
in chow and HFD mice. (E-F) Caspase 3/7 staining in 
Neonatal rat cardiomyocytes treated with different 
concentrations of βHB and their quantification. 
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Next, we translated the in vivo IP findings to in vitro primary culture. Treatment of NRCMs 
with rosiglitazone, a PPAR-γ agonist, enhances the expressions of HMGCS2, BDH1, and PDK4 
consistently in the presence of PA, indicating a positive correlation between PPAR-γ and these 
mitochondrial enzymes (Fig. 5C and 5D). PPAR-γ antagonist G3335 treated cells showed 
significantly prevented the increase of all three concerned metabolic enzymes HMGCS2, 
BDH1 and PDK4 over the baseline. To gain insight into the role of PPAR-γ in mitochondrial 
enzyme expression, we conducted gain- of-function experiment in which we transduced 
NRCMs with carrying wild-type PPAR-γ (WT-PPAR-γ) in the presence of palmitate. PPAR-γ 
overexpression showed a significant increase in the expressions of HMGCS2, BDH1, and PDK 
compared with lacZ control (Fig. 5E & 5F), confirming that activation of PPAR-γ is directly 
responsible for enhanced responsiveness of these mitochondrial metabolic enzymes.
PPAR-γ ablation downregulates the expression of HMGCS2, BDH1, and PDK4 in the diabetic 
LV heart
To explore the functional effects associated with PPAR-γ in vivo, PPAR-γ-/- and their WT 
controls were subjected to HFD treatment. Relative to HFD-WT samples, PPAR-γ-
Fig. 4. HFD-mediated T2D stimulate leads to 
activation and nuclear translocation of PPAR-γ. (A) 
qRT-PCR expression of PPAR-γ mRNA from LV heart 
in bar diagram normalized with GAPDH internal 
control in chow and HFD group. (B-C) PPAR-γ 
immunostaining and its quantification from LV 
heart in chow and HFD group. (D-E) Immunoblot 
showing nuclear and cytosolic expressions of PPAR-γ in chow an HFD group from LV heart extracts and 
their quantifications normalized with Histone3 
and GAPDH for nuclear and cytosolic fractions, 














Fig. 5. PPAR-γ interacts with and upregulates 
HMGCS2, BDH1 and PDK4 expressions. (A-B) Co-
immunoprecipitation of PPAR-γ with its downstream 
molecules HMGCS2, BDH1 and PDK4 from LV heart followed by immunoblot in chow and HFD mice 
and their quantifications (*p<0.05 vs chow). (C-D) 
Neonatal rat cardiomyocytes (NRCMs) treated with 
Rosiglitazone and G3335 in the presence of Palmitic 
acid (PA; 300µM) or Oleic acid (OA; 300µM) for 12h 
followed by immunoblot for PPAR-γ, HMGCS2, BDH1, 
and PDK4 and their quantifications represented 
by bar diagrams normalized with GAPDH (*p<0.05 
vs OA control). (E-F) NRCMs infected with PPAR-γ 
adenovirus or Lac-Z control and treated with 
PA for 12h followed by immunoblot for PPAR-γ, 
HMGCS2, BDH1, and PDK4 and their quantifications 
represented by bar diagrams normalized with 
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/-diabetic heart showed a significant decrease in the levels of HMGCS2, BDH1, and PDK4 
expression (Fig. 6A & 6B). IHC of diabetic LV heart showed similar results as immunoblot 
analysis. Fig. 6C-6E shows increased HMGCS2 and PDK4 immunostaining in HFD-WT hearts 
compared with chow-WT hearts. PPAR-γ ablation in diabetic mice significantly attenuated 
the expressions of the HMGCS2 and PDK4 enzymes compared to WT-HFD group (Fig. 6C-6E). 
BDH1 expression was also significantly decreased in PPAR-γ-/- diabetic hearts compared to 
WT diabetic group (data not shown).
PPAR-γ ablation ameliorates HFD-mediated hyperlipidemic and diabetic changes 
PPAR-γ-/- mice maintained a low level of body weight and blood glucose level throughout 
the experimental period. Final body weight was 20% lower and blood glucose was 30% 
lower in the PPAR-γ-/--HFD mice compared to the WT-HFD group (Fig. 7A & 7B). Glucose 
tolerance and insulin responsiveness were also significantly improved in PPAR-γ-/--HFD 
mice compared to the WT-HFD mice, based on their respective glucose tolerance and insulin 
tolerance results (Fig. 7C & 7D). Although the food intake and calorie intake were comparable 
in both WT-HFD and PPAR-γ-/--HFD animals (Fig. 7E-7F), the storage body fat (both visceral 
and subcutaneous) were found to be significantly high in WT-HFD compared to its chow 
counterpart. Interestingly, PPAR-γ-/--HFD animals significantly ameliorated body fat 
storage compared to WT-HFD animals as described in figure 7G. The reduced glucose uptake 
and its utilization in the WT-HFD group was evident from a significant inhibition in glut4 
receptor expression compared to WT-Chow and PPAR-γ-/- animals (Fig.7H & 7I).
Attenuation in blood glucose level and insulin responsiveness was reflected in the lipid 
profile. TC and free FA levels were significantly reduced (64% and 38%) in the PPAR-γ-/--
HFD mice compared to WT-HFD mice (Fig. 7J & 7K). Serum levels of TG and its tissue 
deposition were also remarkably deceased (53% and 63%) after PPAR-γ ablation even with 
HFD treatment (Fig. 7L-7N).
PPAR-γ deletion restores HFD-mediated changes in cardiac function and prevents 
apoptosis
Recently, PPAR-γ deletion was found to prevent lipotoxicity in heart [54]. Herein, we 
found that PPAR-γ deletion recovers cardiac functions in HFD group. FS, EF, and E/A ratio 
were significantly restored in the PPAR-γ-/--HFD mice compared to the WT-HFD mice (Fig. 
8A & 8C). PPAR-γ deletion did not affect the LVID;d, LVID;s, and LVPW;d in the control group; 
however, it significantly suppressed the increase in these parameters in the diabetic group 
compared to HFD-WT mice (Fig. 8B). Next, we analyzed total collagen content in the mice 
Fig. 6. PPAR-γ ablation downregulates the expression 
of HMGCS2, BDH1 and PDK4 in the diabetic heart. 
(A-B) Immunoblot showing expressions of PPAR-γ, 
HMGCS2, BDH1, and PDK4 from LV heart and their 
quantification with bar diagrams normalized with 
GAPDH in WT and PPAR-γ-/- mice fed with chow 
or HFD. (C-E) Immunostaining with HMGCS2, and 
PDK4 in paraffin embedded LV heart and their 
quantifications in WT and PPAR-γ-/- mice fed with 
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hearts because collagen deposition influences the passive mechanical properties of the 
myocardium and then affects the cardiac performance. WT-HFD heart showed high levels of 
fibrosis, as revealed by collagen deposition from picrosirius red staining and PPAR-γ ablation 
significantly alleviated this diabetic-induced cardiac fibrosis (Fig. 8D & 8E).
To further confirm that PPAR-γ has a protective role after diabetes induction, we analyzed 
the degree of apoptotic cell death with TUNEL staining. We found 3 fold more TUNEL positive 
cells in the LV heart of WT-HFD group compared to WT-chow group, indication of apoptosis 
and cell death. PPAR-γ ablation significantly diminished apoptotic changes in the WT-HFD 
group (Fig. 8F & 8G). Protein expression of 3 major apoptotic markers (i.e., cyt-c, bax, bad) 
was significantly upregulated by chronic HFD treatment in WT mice (2 fold, 2.5 fold, and 
1.7 fold, respectively). However, PPAR-γ deletion significantly prevented the upregulation of 
these apoptotic molecules. Collectively, these data show that PPAR-γ deletion offers cardio-
protection in response to HFD treatment (Fig. 8H & 8I).
DiscussionIn this present study, the impact of chronic HFD treatment on diabetes and cardiac health was investigated from a metabolic approach in terms of lipotoxicity. HFD intake for a chronic term is one of the major underlying factors for T2DM which plays a critical role in the development of the complex phenotype of the cardiac hypertrophy, ventricular dilatation 
Fig. 7. PPAR-γ ablation ameliorates HFD-mediated hyperlipidemic and diabetic changes. Periodic change 
in (A) BW; (B) BG levels in WT and 
PPAR-γ-/- mice fed with chow or 
HFD. (C) Glucose test tolerance; 
(D) Insulin test tolerance in WT-
HFD and PPAR-γ-/-- HFD mice. 
(E-F) Cumulative food intake and calorie intake over time among the experimental groups. (G) Storage body fat composition among 
WT and PPAR-γ-/- . (H-I) Glut4 
expression and its quantification 
from LV heart normalized with 
GAPDH in WT and PPAR-γ-/- mice fed with chow or HFD. Serum levels 
of (J) TC; (K) FFA; and (L) TG in WT 
and PPAR-γ-/- mice fed with chow 
or HFD. (M-N) Oil-red-O staining 
of LV heart and its quantification 
in WT and PPAR-γ-/- mice fed with 
chow or HFD (*p<0.05 chow vs HFD, #p<0.05 WT-HFD vs PPAR-/--HFD).
Figure 7 
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and heart failure [8-10]. Being such an organ that primarily uses lipids as a source of energy, heart is more susceptible against lipotoxicity in long-term exposure to high levels of lipids 
[8, 10]. The pathological pathways and the underline cellular entities linking cellular lipids 
to cardiac dysfunction are obscure. Our objective was to determine whether HFD induced 
T2DM was linked to activate mitochondrial ketogenic enzymes via enhanced PPAR-γ nuclear 
translocation. To investigate the impact of PPAR-γ on T2DM and cardiac dysfunction, we 
used PPAR-γ-/- mice against chronic HFD treatment and compared the findings with that of 
the WT mice. In this study we demonstrated for the first time by performing a cross of CRE-
ERT2-PPAR-γ onto the PPAR-γ –/– background, how the T2DM and cardiac dysfunction can be rescued after prolonged HFD induction.
In the present study, HFD treatment for 16 weeks was found to be associated with 
increased body weight, blood glucose, TC and FA levels. We also found there was lipid 
accumulation in the LV tissue in WT-HFD mice. At the same time there were significant 
reductions in glucose tolerance and insulin responsiveness. These findings established 
the previous reports about the link between HFD intake, obesity and T2DM [55, 56]. 
Echocardiography findings depicted how the cardiac functions were compromised in WT-
HFD group with significantly altered contractile parameters compared to WT-chow mice. 
These outcomes support the preceding findings that reduced cardiac function is associated 
with increased lipids found in patients with obesity and diabetes [55, 57].
Cardiac muscle is the most energy-requiring tissue in the body and primarily uses FAs and in condition such as glucose intolerance and insulin unresponsiveness created by HFD-
driven T2DM, it relies more to lipid-derived FAs [58]. To investigate if cardiac toxicity in diabetic mice is associated with defective mitochondrial function, we found upregulation 
of ketogenic enzymes HMGCS2 and BDH1 and at the same time upregulation of PDK4 that 
regulates FAO enzymes, both at mRNA and protein levels in WT-HFD mice over control. 
As a consequence, the serum ketone body level was also found to be significantly high in 
Fig. 8. PPAR-γ deletion restores HFD-mediated changes in cardiac 
function and prevents apoptosis. (A-C) 
Echocardiographic data showing LVFS, 
LVEF, LVPWd, LVIDd, LVIDs, and E/A 
ratio in M-mode in WT and PPAR-γ-/- mice fed with chow or HFD. (D) Collagen 
deposition with Picrosirius red (200x) in 
paraffin embedded LV heart in WT and 
PPAR-γ-/- mice fed with chow or HFD. 
(E) Semiquantitative analysis of collagen deposition was done by a computer 
imaging system. (F & G) Apoptotic TUNEL 
staining (200x) from LV heart and its 
quantification in WT and PPAR-γ-/- mice fed with chow or HFD. (H-I) Immunoblot from LV heart showing expressions of apoptotic 
molecules Cytochrome-c, Bax and Bad 
followed by quantification normalized 
with GAPDH in WT and PPAR-γ-/- mice fed 
with chow or HFD (*p<0.05 chow vs HFD, #p<0.05 WT-HFD vs PPAR-/--HFD)
Figure 8 
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WT-HFD group compared to WT-chow. To check the cytotoxic effects of the ketone bodies we found when cardiomyocytes were treated in vitro with βOHB, one of the major ketone 
bodies produced by the above mentioned mitochondrial enzymes, majority of the cells die 
within 12 hours’ time period with a LD
50
 value as low as 10 mM. PPARs are transcription factors that function as important regulators of cell differentiation and energy homeostasis. 
Among the 3 subtypes, PPAR-γ acts as an adipogenic factor that regulates the expression 
of genes associated with lipid metabolism [39]. We also checked the expressions of all 3 
members of the PPAR family in WT-Chow and WT-HFD heart (data not shown) both at gene 
and protein levels. Interestingly, only PPAR-γ subtype was expressed considerably after HFD 
induction in LV heart tissue. Not only we saw an overexpression of PPAR-γ in whole tissue 
extract but there was significantly high PPAR-γ level in the nuclear fraction compared to 
the cytosolic fraction, demonstrating activation and nuclear translocation of PPAR-γ induced 
by high concentration of intracellular lipids. This PPAR-γ overexpression in HFD-treated 
heart substantiates the finding of Mafella et al, where they showed hearts of patients having 
greater lipid accumulation also have increased expression of PPAR-γ [59].
Inside the nucleus, PPAR-γ binds to the PPRE in the promoter region of target genes
[39, 45, 46] and modifies their expressions. However, we demonstrated for the first 
time that PPAR-γ activation directly associated to upregulation of HMGCS2, PDK4 and BDH1 
which was not shown before. We verified this association in LV tissue by IP. Also this data was validated by in vitro study where we treated the cells with PPAR-γ agonist (rosiglitazone) or 
antagonist (G3335) and found reciprocal changes in the expressions of HMGCS2, BDH1 and 
PDK4 with changes in PPAR-γ expression. Additionally, we found over expressions of the 
above-mentioned mitochondrial enzymes when cardiomyocytes were infected with PPAR-γ adenovirus.
Findings with WT-HFD mice were reciprocated in PPAR-γ-/- animals. In PPAR-γ-/--HFD 
mice heart, we found downregulation of HMGCS2, BDH1 and PDK4 expressions from their 
corresponding immunoblots and IHC as anticipated. PPAR-γ-/--HFD animals prevented 
escalation in body weight, blood glucose and lipid levels compared to WT- HFD. The former 
group showed improved glucose tolerance and insulin responsiveness reflected by their respective tolerance curves. The above set of data indicates prevention in hyperlipidemia 
and consequent T2DM in PPAR-γ-/- -HFD animals compared to WT-HFD. Improvements in 
cardiac contractile and prevention in fibrotic development in PPAR-γ-/--HFD heart over its 
WT counterpart obviously suggest better cardiac structural and functional health which is 
supported by the fact that PPAR-γ-/-- HFD animals also had diminished TUNEL positive cells and a reciprocal reduction in pro-apoptotic molecules expression in LV heart compared to 
WT-HFD.
In summary, we present data that shows for the first time: 1) HFD mediated activation 
of PPAR-γ is directly associated with HMGCS2, BDH1 and PDK4 upregulation both in vivo and in vitro systems, 2) PPAR-γ mediated metabolic anomalies are directly responsible for 
the generation of T2DM and cardiac dysfunction which can be prevented by PPAR-γ ablation approach.
These findings provide important information regarding the impact of PPAR-γ in lipotoxic T2DM during the development of heart failure and provide new rationale for 
treatment strategies aimed at PPAR-γ antagonism. These results have led us to hypothesize 
that PPAR-γ antagonists might be useful in treatment of patients having metabolic diabetes and cardiac complications.
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